gms | German Medical Science

18th Symposium on Infections in the Immunocompromised Host

International Immunocompromised Host Society

15. to 17.06.2014, Berlin

FungiscopeTM – Global Emerging Fungal Infection Registry

Meeting Abstract

  • K. Wahlers - University Hospital of Cologne, Köln, Germany
  • M.J.G.T. Vehreschild - Germany
  • H. Wisplinghoff - Germany
  • S. de Hoog - Germany
  • J.J. Vehreschild - Germany
  • O.A. Cornely - Germany
  • Fungiscope ECMM/ISHAM Working - Germany

18th Symposium on Infections in the Immunocompromised Host. Berlin, 15.-17.06.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. Doc14ichs46

doi: 10.3205/14ichs46, urn:nbn:de:0183-14ichs464

Veröffentlicht: 3. Juni 2014

© 2014 Wahlers et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: The relevance of emerging invasive fungal diseases (IFD) is increasing. FungiscopeTM is a global registry for emerging IFD with members in >45 countries. The objective is to broaden knowledge on epidemiology, determine clinical patterns, describe and improve diagnostic procedures and therapeutic regimens, and to exchange of clinical isolates among contributors.

Methods: Fungiscope™ uses web-based data capture via www.fungiscope.net. Case enrollment requires cultural, histological, antigen or molecular evidence of IFD. Data collected include demographics, underlying conditions, immunosuppressive medication, clinical signs and symptoms, sites of infection, diagnostic tests, pathogen identification, antifungal treatment, surgical procedures, response to treatment, and survival.

Results: To date, 357 cases have been captured. Mucorales (n=155; 43.4%), Fusarium spp. (n=58; 16.2%), yeasts (n=51; 14.3%), and Dematiaceae (n=34; 9.5%) are the most frequently registered pathogens. Chemotherapy or allogeneic stem cell transplantation were the predominant risk factors (n=243; 68.1%), followed by diabetes (n=68; 19%), intensive care (n=81; 22.7%), and chronic renal disease (n=34; 9.5%). Sites of infection included lung (n=174; 48.7%), followed by blood stream (n=73; 20.4%), paranasal sinuses (n=61; 17.1%), and deep soft tissue (n=54; 15.1%). Favorable outcome was found in 177 (49.6%) patients. All-cause-mortality and mortality attributable to IFD was 47.1% and 35.9%, respectively.

Conclusion: We documented a broad biological diversity of IFD across Europe, Asia and the Americas. Patients with malignancies are at particular risk. Mortality is high. Further investigators are invited to contribute to FungiscopeTM.

Keywords: Rare fungal infections, web-based registry